96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial

- Farrell, Michael, Shahbazi, Jeyran, Nielsen, Suzanne, Dunlop, Adrian, Dore, Gregory J., McDonough, Michael, Montebello, Mark, Weiss, Rob, Rodgers, Craig, Cook, Jon, Degenhardt, Louisa, Chambers, Mark, Byrne, Marianne, Gholami, Jaleh, Zahra, Emma, Grebely, Jason, Lintzeris, Nicholas, Larance, Briony, Ali, Robert

Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence

- Farrell, Michael, Shahbazi, Jeyran, Byrne, Marianne, Grebely, Jason, Lintzeris, Nicholas, Chambers, Mark, Larance, Briony, Ali, Robert, Nielsen, Suzanne, Dunlop, Adrian, Dore, Gregory J., McDonough, Michael, Montebello, Mark, Nicholas, Thomas, Weiss, Rob, Rodgers, Craig, Cook, Jon, Degenhardt, Louisa

Assessing the concurrent validity, inter-rater reliability and test-re-test reliability of the Australian Treatment Outcomes Profile (ATOP) in alcohol and opioid treatment populations

- Deacon, Rachel M., Mammen, Kristie, Bruno, Raimondo, Mills, Llewellyn, Dunlop, Adrian, Holmes, Jennifer, Jefferies, Meryem, Hall, Michelle, Shakeshaft, Anthony, Farrell, Michael, Graham, Robert, Lintzeris, Nicholas

Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients’ experiences in Australia

- Barnett, Anthony, Savic, Michael, Lintzeris, Nicholas, Bathish, Ramez, Arunogiri, Shalini, Dunlop, Adrian J., Haber, Paul, Graham, Robert, Hayes, Vicky, Lubman, Dan I.

The impact of blood-borne viruses on cause-specific mortality among opioid dependent people: an Australian population-based cohort study

- Vajdic, Claire M., Pour, Sadaf Marashi, Amin, Jananki, Burns, Lucinda, Degenhardt, Louise, Olivier, Jake, Swart, Alexander, O'Connell, Dianne L., Falster, Michael O., Meagher, Nicola S., Mao, Limin, Grulich, Andrew E., Randall, Deborah A.